| Pharmaceutical Information |
| Drug Name |
Trifarotene |
| Drug ID |
BADD_D02601 |
| Description |
Trifarotene is a topical retinoid cream used in the treatment of acne vulgaris that was first approved for use in the United States in October 2019.[L9013] Retinoids are a class of medications structurally and functionally analogous to [vitamin A], though later generation retinoids such as trifarotene and [adapalene] bear little structural resemblance to vitamin A and are analogous only in function.[A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older, less selective retinoids.[A187054] |
| Indications and Usage |
Trifarotene is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.[L9013] |
| Marketing Status |
approved; investigational |
| ATC Code |
D10AD06 |
| DrugBank ID |
DB12808
|
| KEGG ID |
D11225
|
| MeSH ID |
C000629420
|
| PubChem ID |
11518241
|
| TTD Drug ID |
D06FOU
|
| NDC Product Code |
17337-0432; 0299-5935 |
| UNII |
0J8RN2W0HK
|
| Synonyms |
trifarotene | Aklief | CD5789 |
|
| Chemical Information |
| Molecular Formula |
C29H33NO4 |
| CAS Registry Number |
895542-09-3 |
| SMILES |
CC(C)(C)C1=C(C=CC(=C1)C2=C(C=CC(=C2)C3=CC=C(C=C3)C(=O)O)OCCO)N4CCCC4 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
